Pharus Sicav Medical Innovation
| Net Asset Value | 107,90 EUR |
|---|---|
| Fund Size | 1.718.251 EUR |
| Launch Date | 2 ott 2012 |
| Benchmark | BENCHMARK COMPOSITE 17389 |
| Sicav | PHARUS SICAV |
|---|---|
| Management Company | PHARUS MANAGEMENT LUX SA |
| Investment Manager | Pharus Asset Management SA |
Risk & reward profile
- 1
- 2
- 3
- 4
- 5
- 6
- 7
Top positive contributors during the month included Humana and Novo Nordisk, while Vertex Pharmaceuticals and Moderna were among the main detractors.
During the month, we increased our exposure to Eli Lilly, a market leader in diabetes treatment, and added Zoetis to the portfolio, a global leader in animal health.
The portfolio remains focused on global leaders in the Health Care sector trading at discounted valuations. We believe the portfolio offers a significant valuation discount, driven by a sector-specific recession and a 25% drop in earnings, which has created an opportunity in the sector that typically arises only every 5 to 10 years.
Last updated on 17.09.2025
| Euro Fx Curr Fut Sep25 | 85.02 % |
|---|---|
| Eli Lilly & Co | 4.79 % |
| Johnson & Johnson | 4.03 % |
| Cvs Health Corp | 3.97 % |
| Merck & Co. Inc. | 3.95 % |
| Pfizer Inc | 3.9 % |
| Humana Inc | 3.67 % |
| Abbvie Inc | 3.56 % |
| Novo Nordisk A/s-b | 3.27 % |
| Roche Holding Ag-genusschein | 3.15 % |
SFDR Article: 8
The Sub-Fund does not have as its objective a sustainable investment, but promotes social characteristics with a proportion of sustainable investments with a social objective of at least 80% of its assets.
Objectives
The Sub-Fund’s sustainable investment objective is to select companies promoting peaceful, just and inclusive principles, evidencing a strong Sustainability rating and following good governance practices, while avoids the exposure to companies involved in controversial weapons production, tobacco production, adult entertainment, gambling sector, violation of United Nation Global Pact, as per the internal ESG policy defined.
Social characteristics promoted are mainly represented by the below:
- Security of products and health
- Human rights and human dignity
- Equality labour conditions
- Governance
Asset Allocation
All the investments are assessed ex ante by an independent external ESG advisor and need to be compliant with including criteria and not in breach with excluding criteria set out on the applicable ESG policy. Investments aligned with E/S characteristic must attain the social characteristics promoted by the financial product and must represent at least 80% of the Sub-fund’s asset. Sustainable investments are investments in securities whose rating is considered acceptable and which comply with the excluding criteria set out in the ESG policy applicable. Other Investments include cash, derivatives, bonds and equities which do not have any ESG rating or with a weak ESG rating and can represent up to 20% of the portfolio.
Principal adverse impacts
This financial product considers PAI and monitors additional PAI with the support of an ESG Advisor that produces, on quarterly basis, a complete report that illustrates the PAI and the results for the portfolio. Furthermore, the Sub-Fund focuses on the PAI number 10 and 11. PAI number 10 monitors/takes into consideration weight of company with severe violation of UNGC principles or OECD guidelines for multinationals. PAI number 11 refers to weight of companies without mechanism for monitoring the compliance with UNGC principles and OECD guidelines.
Binding elements
The exclusion criteria applied to the investment universe, are aimed to exclude companies
31.03.2025